Team |
Sarah Compton, PhD
Sarah Compton, PhD

Sarah Compton, PhD

Principal Scientist

Technology Development

Sarah is focused on developing novel therapeutic gene editing technologies using RNA guided nucleases and base editors.

She previously held several positions in biotechnology and early-stage drug discovery companies including Zen-Bio, Curl Bio and Verge Therapeutics, where she focused on developing cell-based disease models for high throughput screening and small molecule drug discovery.

Sarah earned her Ph.D. in Pharmacology and Toxicology from the Medical College of Virginia where she studied the functional assembly of the telomerase enzyme and telomere maintenance pathways. She continued her studies in telomere biology and DNA repair as a Research Assistant Professor at The University of North Carolina at Chapel Hill, before transitioning to industry.

Connect with
Sarah
https://www.linkedin.com/in/sarah-compton-4333b39/

Visionary science, driven by visionary values.

Our Mission

To rewrite the future by curing disease, making any edit, anywhere.

Our Vision

To pave the way to faster, safer, gene editing therapeutics that cure disease and improve patient lives.

Our Values

We’re guided by curiosity, rigor, and integrity. We believe in discovery and unlimited potential. We care about science and the lives of patients.